Matteo Marchesini

Matteo Marchesini

Auto-generated profile, based on publicly available information

Matteo Marchesini

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2014 in Nature
Verified
Journal Article
Closed access
PDF file
AVAndrea Viale
Andrea Viale
PPPiergiorgio Pettazzoni
Piergiorgio Pettazzoni
CLCostas Lyssiotis
Costas Lyssiotis
HYHaoqiang Ying
Haoqiang Ying
NSNora Sánchez
Nora Sánchez
GDGiulio F. Draetta
Giulio F. Draetta

1 July 2017 in Cancer Cell
Verified
Journal Article
Closed access
MMMatteo Marchesini
Matteo Marchesini
YOYamini Ogoti
Yamini Ogoti
EFElena Fiorini
Elena Fiorini
ASAnil Aktas Samur
Anil Aktas Samur
LNLuigi Nezi
Luigi Nezi
SCSimona Colla
Simona Colla

1 May 2015 in Cancer Cell
Verified
Journal Article
Closed access
SCSimona Colla
Simona Colla
DODerrick Sek Tong Ong
Derrick Sek Tong Ong
YOYamini Ogoti
Yamini Ogoti
MMMatteo Marchesini
Matteo Marchesini
NMNipun A. Mistry
Nipun A. Mistry
RDRonald A. Depinho
Ronald A. Depinho

12 March 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PPPiergiorgio Pettazzoni
Piergiorgio Pettazzoni
AVAndrea Viale
Andrea Viale
PSParantu Shah
Parantu Shah
ACAlessandro Carugo
Alessandro Carugo
HYHaoqiang Ying
Haoqiang Ying
GDGiulio Draetta
Giulio Draetta
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we compared KRAS* genetic extinction with pharmacologic inhibition of MEK1 in tumor spheres and in vivo. KRAS* ablation blocked proliferation and induced apoptosis, whereas MEK1 inhibition exerted cytostatic effects. Proteomic analysis evidenced that MEK1 inhibition was accompanied by a sustained activation of the PI3K–AKT–MTOR pathway and by the activation of AXL, PDGFRa, and HER1–2 receptor tyrosine kinases (RTK) expressed in a large proportion of human PDAC samples analyzed. Although single inhibition of each RTK alone or plus MEK1 inhibitors was ineffective, a combination of inhibitors targeting all three coactivated RTKs and MEK1 was needed to inhibit proliferation and induce apoptosis in both mouse and human low-passage PDAC cultures. Importantly, constitutive AKT activation, which may mimic the fraction of AKT2-amplified PDAC, was able to bypass the induction of apoptosis caused by KRAS* ablation, highlighting a potential inherent resistance mechanism that may inform the clinical application of MEK inhibitor therapy. This study suggests that combinatorial-targeted therapies for pancreatic cancer must be informed by the activation state of each putative driver in a given treatment context. In addition, our work may offer explanative and predictive power in understanding why inhibitors of EGFR signaling fail in PDAC treatment and how drug resistance mechanisms may arise in strategies to directly target KRAS. Cancer Res; 75(6); 1091–101. ©2015 AACR.

Verified
Journal Article
Open access
PDF file
EFElena Follini
Elena Follini
MMMatteo Marchesini
Matteo Marchesini
RGRoti Giovanni
Roti Giovanni
Chemoresistance is a major cause of recurrence and death from T-cell acute lymphoblastic leukemia (T-ALL), both in adult and pediatric patients. In the majority of cases, drug-resistant disease is treated by selecting a combination of other drugs, without understanding the molecular mechanisms by which malignant cells escape chemotherapeutic treatments, even though a more detailed genomic characterization and the identification of actionable disease targets may enable informed decision of new agents to improve patient outcomes. In this work, we describe pathways of resistance to common chemotherapeutic agents including glucocorticoids and review the resistance mechanisms to targeted therapy such as IL7R, PI3K-AKT-mTOR, NOTCH1, BRD4/MYC, Cyclin D3: CDK4/CDK6, BCL2 inhibitors, and selective inhibitors of nuclear export (SINE). Finally, to overcome the limitations of the current trial-and-error method, we summarize the experiences of anti-cancer drug sensitivity resistance profiling (DSRP) approaches as a rapid and relevant strategy to infer drug activity and provide functional information to assist clinical decision one patient at a time.

9 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DODerrick Sek Tong Ong
Derrick Sek Tong Ong
BHBaoli Hu
Baoli Hu
YHYan Wing Ho
Yan Wing Ho
CSCharles-Etienne Gabriel Sauvé
Charles-Etienne Gabriel Sauvé
CBChristopher A. Bristow
Christopher A. Bristow
RDRonald A. Depinho
Ronald A. Depinho
An integrated genomic and functional analysis to elucidate DNA damage signaling factors promoting self-renewal of glioma stem cells (GSCs) identified proliferating cell nuclear antigen (PCNA)-associated factor (PAF) up-regulation in glioblastoma. PAF is preferentially overexpressed in GSCs. Its depletion impairs maintenance of self-renewal without promoting differentiation and reduces tumor-initiating cell frequency. Combined transcriptomic and metabolomic analyses revealed that PAF supports GSC maintenance, in part, by influencing DNA replication and pyrimidine metabolism pathways. PAF interacts with PCNA and regulates PCNA-associated DNA translesion synthesis (TLS); consequently, PAF depletion in combination with radiation generated fewer tumorspheres compared with radiation alone. Correspondingly, pharmacological impairment of DNA replication and TLS phenocopied the effect of PAF depletion in compromising GSC self-renewal and radioresistance, providing preclinical proof of principle that combined TLS inhibition and radiation therapy may be a viable therapeutic option in the treatment of glioblastoma multiforme (GBM).